Loading...
•
Sep 30, 2024
Korro Bio Q3 2024 Earnings Report
Reported third quarter financial results and provided business updates.
Key Takeaways
Korro Bio reported its third quarter 2024 financial results, highlighting a regulatory filing submission, the formation of a Clinical Advisory Board, and a collaboration agreement with Novo Nordisk. The company ended the quarter with $169.1 million in cash, cash equivalents, and marketable securities, expecting this to fund operations into the second half of 2026.
Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD).
Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team.
Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro’s proprietary OPERATM platform.
Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities with a cash runway into the second half of 2026.
Forward Guidance
Korro Bio anticipates several milestones, including the first participant dosing of KRRO-110 in Q1 2025, interim Phase 1/2 clinical study readout for KRRO-110 in PiZZ patients in the second half of 2025, and completion of the Phase 1/2 clinical study for KRRO-110 expected in 2026.
Positive Outlook
- First participant dosing of KRRO-110 expected in the first quarter of 2025.
- Interim Phase 1/2 clinical study readout for KRRO-110 in PiZZ patients anticipated in the second half of 2025.
- Completion of the Phase 1/2 clinical study for KRRO-110 expected in 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...